SFX by Ex Libris Inc.

Title:	Drug Regulatory Systems Must Foster Innovation
Source:	Science [0036-8075] Schellekens, Huub yr:2011

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Fitzpatrick, John M. "Change and innovation." BJU international 108.4 (2011).
description	2.	Ebbers, Hans C. "Today's challenges in pharmacovigilance: what can we learn from epoetins?" Drug safety 34.4 (2011): 273-287.
description	3.	Millstone, E. "Risk regulation and administrative constitutionalism." Journal of risk research 11.8 (2008): 1072-1076.
description	4.	Crommelin, Daan J A J. "The therapeutic equivalence of complex drugs." Regulatory toxicology and pharmacology 59.1 (2010): 176-183.
description	5.	Blumenson, E. "How to construct an underclass, or how the war on drugs became a war on education." The journal of gender, race, and justice 6.1 (2002): 61-473.
description	6.	Hyrkäs, K. "Leading innovation and change." Journal of nursing management 18.1 (2010): 1-3.
description	7.	Derrick, S. "Change inspires innovation." Marketing. 18-19.
description	8.	Maslach, D. "Change and persistence with failed technological innovation." Strategic Management Journal 37.4 (2014): 714-723.
description	9.	ODoherty, D. "Paradox, Tensions and Dualities of Innovation and Change." Organization studies 34.10 (2013): 1575-1738.
description	10.	Volpe, M. "2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer." High blood pressure & cardiovascular prevention 18.1 (2011): 37-40.
description	11.	Kalisch, S. "Preparation of Nursing Students for Change and Innovation." Western journal of nursing research 32.2 (2010): 157-167.
description	12.	Hawdon, E. "The role of presidential rhetoric in the creation of a moral panic: Reagan, Bush, and the war on drugs." Deviant Behavior 22.5 (2001): 419-445.
description	13.	Sloane, R. "Social media and pharmacovigilance: A review of the opportunities and challenges." British journal of clinical pharmacology 80.4 (2015): 910-920.
description	14.	Bennett, CL. "Long-term follow-up of recombinant human erythropoietin (epoetin) induced pure red cell aplasia (PRCA): A comparison of data collected through active and passive pharmacovigilance efforts." Blood 104.11 (2004): 415-415.
description	15.	"Film Reviews: "Half Nelson"." Cinéaste 32.1 (2006): 56-58.
description	16.	Pirozynski, S. "Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?: A Review of the New EU Legislation on Pharmacovigilance." Drug safety 34.3 (2011): 187-97.
description	17.	Shen, Y. "Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line." Journal of biological chemistry 272.6 (1997): 3550-3553.
description	18.	Millstone, E. "Food, Risk and Politics: Scare, scandal and crisis - insights into the risk politics of food safety." Social policy and administration 44.7 (2010): 867-869.
description	19.	Nicolau, Jose C. "Differences Among Low-Molecular-Weight Heparins: Evidence in Patients With Acute Coronary Syndromes." Journal of cardiovascular pharmacology 53.6 (2009): 440-445.
description	20.	Morrissey, Michael, M. "Ethnicity and race in drug and alcohol research." Health Sociology Review 14.2 (2005): 111-120.